Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Surender Mohan Kharbanda, Ph.D., Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01CA075216 (KHARBANDA, SURENDER) Aug 5, 1997 - Jul 31, 2000
    Role: Principal Investigator

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Mehrotra N, Anees M, Tiwari S, Kharbanda S, Singh H. Polylactic acid based polymeric nanoparticle mediated co-delivery of navitoclax and decitabine for cancer therapy. Nanomedicine. 2023 01; 47:102627. PMID: 36410699.
    Citations:    Fields:    Translation:HumansAnimals
  2. Tiwari S, Kaur H, Anees M, Gupta P, Dalela M, Kharbanda S, Singh H. Co-encapsulation of PI3-Kd/HDAC6 dual inhibitor and Navitoclax in Quatramer™ nanoparticles for synergistic effect in ER+ breast cancer. Int J Pharm. 2022 Nov 25; 628:122343. PMID: 36341921.
    Citations:    Fields:    Translation:AnimalsCells
  3. Tiwari S, Kharbanda S, Singh H. Quatramer™ mediated co-delivery of PI3-Kd/HDAC6 dual inhibitor augments the anti-cancer efficacy of Epirubicin in breast cancer. Eur J Pharm Biopharm. 2022 Oct; 179:184-193. PMID: 36087881.
    Citations:    Fields:    Translation:AnimalsCells
  4. Anees M, Tiwari S, Mehrotra N, Kharbanda S, Singh H. Development and evaluation of PLA based hybrid block copolymeric nanoparticles for systemic delivery of pirarubicin as an anti-cancer agent. Int J Pharm. 2022 May 25; 620:121761. PMID: 35472512.
    Citations:    Fields:    Translation:AnimalsCells
  5. Mehrotra N, Kharbanda S, Singh H. BH3 mimetics in cancer therapy and their future perspectives with nanodelivery. Nanomedicine (Lond). 2021 06; 16(13):1067-1070. PMID: 33904325.
    Citations:    Fields:    Translation:Humans
  6. Mehrotra N, Kharbanda S, Singh H. Peptide-based combination nanoformulations for cancer therapy. Nanomedicine (Lond). 2020 09; 15(22):2201-2217. PMID: 32914691.
    Citations: 4     Fields:    Translation:Humans
  7. Li W, Zhang N, Jin C, Long MD, Rajabi H, Yasumizu Y, Fushimi A, Yamashita N, Hagiwara M, Zheng R, Wang J, Kui L, Singh H, Kharbanda S, Hu Q, Liu S, Kufe D. MUC1-C drives stemness in progression of colitis to colorectal cancer. JCI Insight. 2020 06 18; 5(12). PMID: 32427590.
    Citations: 13     Fields:    Translation:HumansAnimalsCells
  8. Thakur A, Tawa GJ, Henderson MJ, Danchik C, Liu S, Shah P, Wang AQ, Dunn G, Kabir M, Padilha EC, Xu X, Simeonov A, Kharbanda S, Stone R, Grewal G. Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors. J Med Chem. 2020 04 23; 63(8):4256-4292. PMID: 32212730.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  9. Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H. Corrigendum to 'Concomitant delivery of paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy' NANO 14 (2018) 1301-1313. Nanomedicine. 2018 10; 14(7):2129. PMID: 30048637.
    Citations: 1     Fields:    
  10. Panchamoorthy G, Jin C, Raina D, Bharti A, Yamamoto M, Adeebge D, Zhao Q, Bronson R, Jiang S, Li L, Suzuki Y, Tagde A, Ghoroghchian PP, Wong KK, Kharbanda S, Kufe D. Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate. JCI Insight. 2018 06 21; 3(12). PMID: 29925694.
    Citations: 15     Fields:    Translation:HumansAnimalsCells
  11. Hiraki M, Maeda T, Mehrotra N, Jin C, Alam M, Bouillez A, Hata T, Tagde A, Keating A, Kharbanda S, Singh H, Kufe D. Targeting MUC1-C suppresses BCL2A1 in triple-negative breast cancer. Signal Transduct Target Ther. 2018; 3:13. PMID: 29760958.
    Citations: 15     Fields:    
  12. Gupta D, Kumar M, Tyagi P, Kapoor S, Tyagi A, Barman TK, Kharbanda S, Kufe D, Singh H. Concomitant Delivery of Paclitaxel and NuBCP-9 peptide for synergistic enhancement of cancer therapy. Nanomedicine. 2018 06; 14(4):1301-1313. PMID: 29641982; PMCID: PMC6175673.
    Citations: 4     Fields:    Translation:HumansCells
  13. Shukla V, Dalela M, Vij M, Weichselbaum R, Kharbanda S, Ganguli M, Kufe D, Singh H. Systemic delivery of the tumor necrosis factor gene to tumors by a novel dual DNA-nanocomplex in a nanoparticle system. Nanomedicine. 2017 07; 13(5):1833-1839. PMID: 28343015.
    Citations: 3     Fields:    Translation:Humans
  14. Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer. 2017 02 02; 16(1):33. PMID: 28153010; PMCID: PMC5290603.
    Citations: 18     Fields:    Translation:HumansAnimalsCells
  15. Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget. 2016 Jun 28; 7(26):38974-38987. PMID: 27259275.
    Citations: 23     Fields:    Translation:HumansCells
  16. Hiraki M, Suzuki Y, Alam M, Hinohara K, Hasegawa M, Jin C, Kharbanda S, Kufe D. MUC1-C Stabilizes MCL-1 in the Oxidative Stress Response of Triple-Negative Breast Cancer Cells to BCL-2 Inhibitors. Sci Rep. 2016 05 24; 6:26643. PMID: 27217294; PMCID: PMC4877578.
    Citations: 17     Fields:    Translation:HumansCells
  17. Dalela M, Shrivastav TG, Kharbanda S, Singh H. pH-Sensitive Biocompatible Nanoparticles of Paclitaxel-Conjugated Poly(styrene-co-maleic acid) for Anticancer Drug Delivery in Solid Tumors of Syngeneic Mice. ACS Appl Mater Interfaces. 2015 Dec 09; 7(48):26530-48. PMID: 26528585.
    Citations: 11     Fields:    Translation:AnimalsCells
  18. Raina D, Agarwal P, Lee J, Bharti A, McKnight CJ, Sharma P, Kharbanda S, Kufe D. Characterization of the MUC1-C Cytoplasmic Domain as a Cancer Target. PLoS One. 2015; 10(8):e0135156. PMID: 26267657; PMCID: PMC4534190.
    Citations: 37     Fields:    Translation:HumansCells
  19. Hasegawa M, Sinha RK, Kumar M, Alam M, Yin L, Raina D, Kharbanda A, Panchamoorthy G, Gupta D, Singh H, Kharbanda S, Kufe D. Intracellular Targeting of the Oncogenic MUC1-C Protein with a Novel GO-203 Nanoparticle Formulation. Clin Cancer Res. 2015 May 15; 21(10):2338-47. PMID: 25712682; PMCID: PMC4433879.
    Citations: 30     Fields:    Translation:HumansAnimalsCells
  20. Kumar M, Singh G, Sharma S, Gupta D, Bansal V, Arora V, Bhat M, Srivastava SK, Sapra S, Kharbanda S, Dinda AK, Singh H. Intracellular delivery of peptide cargos using iron oxide based nanoparticles: studies on antitumor efficacy of a BCL-2 converting peptide, NuBCP-9. Nanoscale. 2014 Nov 06; 6(23):14473-83. PMID: 25340469.
    Citations: 1     Fields:    Translation:HumansAnimalsCells
  21. Kumar M, Gupta D, Singh G, Sharma S, Bhat M, Prashant CK, Dinda AK, Kharbanda S, Kufe D, Singh H. Novel polymeric nanoparticles for intracellular delivery of peptide Cargos: antitumor efficacy of the BCL-2 conversion peptide NuBCP-9. Cancer Res. 2014 Jun 15; 74(12):3271-81. PMID: 24741005.
    Citations: 20     Fields:    Translation:HumansAnimalsCells
  22. Liu S, Yin L, Stroopinsky D, Rajabi H, Puissant A, Stegmaier K, Avigan D, Kharbanda S, Kufe D, Stone R. MUC1-C oncoprotein promotes FLT3 receptor activation in acute myeloid leukemia cells. Blood. 2014 Jan 30; 123(5):734-42. PMID: 24282218; PMCID: PMC3907758.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  23. Uchida Y, Raina D, Kharbanda S, Kufe D. Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol Ther. 2013 Feb; 14(2):127-34. PMID: 23114713.
    Citations: 19     Fields:    Translation:HumansCells
  24. Kumar M, Singh G, Arora V, Mewar S, Sharma U, Jagannathan NR, Sapra S, Dinda AK, Kharbanda S, Singh H. Cellular interaction of folic acid conjugated superparamagnetic iron oxide nanoparticles and its use as contrast agent for targeted magnetic imaging of tumor cells. Int J Nanomedicine. 2012; 7:3503-16. PMID: 22848174.
    Citations: 21     Fields:    Translation:HumansCells
  25. Nelson EA, Walker SR, Xiang M, Weisberg E, Bar-Natan M, Barrett R, Liu S, Kharbanda S, Christie AL, Nicolais M, Griffin JD, Stone RM, Kung AL, Frank DA. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. Genes Cancer. 2012 Jul; 3(7-8):503-11. PMID: 23264850.
    Citations: 53     
  26. Rajabi H, Ahmad R, Jin C, Joshi MD, Guha M, Alam M, Kharbanda S, Kufe D. MUC1-C oncoprotein confers androgen-independent growth of human prostate cancer cells. Prostate. 2012 Nov; 72(15):1659-68. PMID: 22473899.
    Citations: 28     Fields:    Translation:HumansCells
  27. Raina D, Ahmad R, Rajabi H, Panchamoorthy G, Kharbanda S, Kufe D. Targeting cysteine-mediated dimerization of the MUC1-C oncoprotein in human cancer cells. Int J Oncol. 2012 May; 40(5):1643-9. PMID: 22200620.
    Citations: 51     Fields:    Translation:HumansCells
  28. Yang X, Liu S, Kharbanda S, Stone RM. AKT1 induces caspase-mediated cleavage of the CDK inhibitor p27Kip1 during cell cycle progression in leukemia cells transformed by FLT3-ITD. Leuk Res. 2012 Feb; 36(2):205-11. PMID: 22142798.
    Citations: 3     Fields:    Translation:HumansCells
  29. Yin L, Wu Z, Avigan D, Rosenblatt J, Stone R, Kharbanda S, Kufe D. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70. PMID: 21422470; PMCID: PMC3100696.
    Citations: 22     Fields:    Translation:HumansCells
  30. Raina D, Kosugi M, Ahmad R, Panchamoorthy G, Rajabi H, Alam M, Shimamura T, Shapiro GI, Supko J, Kharbanda S, Kufe D. Dependence on the MUC1-C oncoprotein in non-small cell lung cancer cells. Mol Cancer Ther. 2011 May; 10(5):806-16. PMID: 21421804.
    Citations: 90     Fields:    Translation:HumansAnimalsCells
  31. Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T, Kharbanda S, Kufe D. MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 2011 Feb 15; 4(160):ra9. PMID: 21325207.
    Citations: 57     Fields:    Translation:HumansCells
  32. Yin L, Ahmad R, Kosugi M, Kawano T, Avigan D, Stone R, Kharbanda S, Kufe D. Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein. Cancer Biol Ther. 2010 Sep 01; 10(5):483-91. PMID: 20592495.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  33. Ahmad R, Liu S, Weisberg E, Nelson E, Galinsky I, Meyer C, Kufe D, Kharbanda S, Stone R. Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation. Mol Cancer Res. 2010 Jul; 8(7):986-93. PMID: 20571062.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  34. Yin L, Ahmad R, Kosugi M, Kufe T, Vasir B, Avigan D, Kharbanda S, Kufe D. Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol. 2010 Aug; 78(2):166-74. PMID: 20444960.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  35. Huang L, Liao X, Beckett M, Li Y, Khanna KK, Wang Z, Kharbanda S, Weichselbaum R, Kufe D. MUC1-C Oncoprotein Interacts Directly with ATM and Promotes the DNA Damage Response to Ionizing Radiation. Genes Cancer. 2010 Mar; 1(3):239-250. PMID: 20865059.
    Citations: 12     
  36. Joshi MD, Ahmad R, Yin L, Raina D, Rajabi H, Bubley G, Kharbanda S, Kufe D. MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther. 2009 Nov; 8(11):3056-65. PMID: 19887552.
    Citations: 45     Fields:    Translation:HumansAnimalsCells
  37. Ahmad R, Raina D, Joshi MD, Kawano T, Ren J, Kharbanda S, Kufe D. MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. Cancer Res. 2009 Sep 01; 69(17):7013-21. PMID: 19706766.
    Citations: 111     Fields:    Translation:HumansCells
  38. Raina D, Ahmad R, Joshi MD, Yin L, Wu Z, Kawano T, Vasir B, Avigan D, Kharbanda S, Kufe D. Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res. 2009 Jun 15; 69(12):5133-41. PMID: 19491255.
    Citations: 94     Fields:    Translation:HumansAnimalsCells
  39. Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation. Int J Oncol. 2009 Jun; 34(6):1691-9. PMID: 19424588.
    Citations: 38     Fields:    Translation:HumansCells
  40. Raina D, Ahmad R, Chen D, Kumar S, Kharbanda S, Kufe D. MUC1 oncoprotein suppresses activation of the ARF-MDM2-p53 pathway. Cancer Biol Ther. 2008 Dec; 7(12):1959-67. PMID: 18981727; PMCID: PMC3023907.
    Citations: 10     Fields:    Translation:HumansCells
  41. Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res. 2008 Aug 01; 68(15):6136-44. PMID: 18676836.
    Citations: 42     Fields:    Translation:HumansCells
  42. Ahmad R, Raina D, Trivedi V, Ren J, Rajabi H, Kharbanda S, Kufe D. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol. 2007 Dec; 9(12):1419-27. PMID: 18037881.
    Citations: 111     Fields:    Translation:HumansCells
  43. Ramasamy S, Duraisamy S, Barbashov S, Kawano T, Kharbanda S, Kufe D. The MUC1 and galectin-3 oncoproteins function in a microRNA-dependent regulatory loop. Mol Cell. 2007 Sep 21; 27(6):992-1004. PMID: 17889671; PMCID: PMC4217170.
    Citations: 108     Fields:    Translation:HumansAnimalsCells
  44. Yin L, Kharbanda S, Kufe D. Mucin 1 oncoprotein blocks hypoxia-inducible factor 1alpha activation in a survival response to hypoxia. J Biol Chem. 2007 Jan 05; 282(1):257-66. PMID: 17102128.
    Citations: 43     Fields:    Translation:HumansCells
  45. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem. 2006 Nov 24; 281(47):35764-9. PMID: 16998237.
    Citations: 109     Fields:    Translation:HumansCells
  46. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, Kufe D. MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J. 2006 Aug 23; 25(16):3774-83. PMID: 16888623; PMCID: PMC1553184.
    Citations: 39     Fields:    Translation:HumansCells
  47. Kawano T, Agata N, Kharbanda S, Avigan D, Kufe D. A novel isocoumarin derivative induces mitotic phase arrest and apoptosis of human multiple myeloma cells. Cancer Chemother Pharmacol. 2007 Feb; 59(3):329-35. PMID: 16830153.
    Citations: 8     Fields:    Translation:HumansCells
  48. Duraisamy S, Ramasamy S, Kharbanda S, Kufe D. Distinct evolution of the human carcinoma-associated transmembrane mucins, MUC1, MUC4 AND MUC16. Gene. 2006 May 24; 373:28-34. PMID: 16500040.
    Citations: 48     Fields:    Translation:HumansAnimals
  49. Huang L, Chen D, Liu D, Yin L, Kharbanda S, Kufe D. MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin. Cancer Res. 2005 Nov 15; 65(22):10413-22. PMID: 16288032.
    Citations: 132     Fields:    Translation:HumansCells
  50. Agata N, Nogi H, Bamberg M, Milhollen M, Pu M, Weitman S, Kharbanda S, Kufe D. The angiogenesis inhibitor NM-3 is active against human NSCLC xenografts alone and in combination with docetaxel. Cancer Chemother Pharmacol. 2005 Dec; 56(6):610-4. PMID: 15947930.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  51. Raina D, Pandey P, Ahmad R, Bharti A, Ren J, Kharbanda S, Weichselbaum R, Kufe D. c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic response to DNA damage. J Biol Chem. 2005 Mar 25; 280(12):11147-51. PMID: 15657060.
    Citations: 21     Fields:    Translation:HumansCells
  52. Agata N, Nogi H, Milhollen M, Kharbanda S, Kufe D. 2-(8-Hydroxy-6-methoxy-1-oxo-1H-2-benzopyran-3-yl)propionic acid, a small molecule isocoumarin, potentiates dexamethasone-induced apoptosis of human multiple myeloma cells. Cancer Res. 2004 Dec 01; 64(23):8512-6. PMID: 15574755.
    Citations: 7     Fields:    Translation:HumansCells
  53. Yu D, Khan E, Khaleque MA, Lee J, Laco G, Kohlhagen G, Kharbanda S, Cheng YC, Pommier Y, Bharti A. Phosphorylation of DNA topoisomerase I by the c-Abl tyrosine kinase confers camptothecin sensitivity. J Biol Chem. 2004 Dec 10; 279(50):51851-61. PMID: 15448168.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  54. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem. 2004 May 14; 279(20):20607-12. PMID: 14999001.
    Citations: 75     Fields:    Translation:AnimalsCells
  55. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell. 2004 Feb; 5(2):163-75. PMID: 14998492; PMCID: PMC4217165.
    Citations: 146     Fields:    Translation:Cells
  56. Huang L, Ren J, Chen D, Li Y, Kharbanda S, Kufe D. MUC1 cytoplasmic domain coactivates Wnt target gene transcription and confers transformation. Cancer Biol Ther. 2003 Nov-Dec; 2(6):702-6. PMID: 14688481.
    Citations: 43     Fields:    Translation:HumansAnimalsCells
  57. Li Y, Liu D, Chen D, Kharbanda S, Kufe D. Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene. 2003 Sep 04; 22(38):6107-10. PMID: 12955090.
    Citations: 92     Fields:    Translation:HumansAnimalsCells
  58. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res. 2003 Aug; 1(10):765-75. PMID: 12939402.
    Citations: 45     Fields:    Translation:HumansCells
  59. Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S, Anderson KC. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6. PMID: 12665525.
    Citations: 53     Fields:    Translation:HumansCells
  60. Ren X, Cao C, Zhu L, Yoshida K, Kharbanda S, Weichselbaum R, Kufe D. Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor. Cancer Biol Ther. 2002 Nov-Dec; 1(6):703-8. PMID: 12642697.
    Citations: 5     Fields:    Translation:HumansCells
  61. Raina D, Mishra N, Kumar S, Kharbanda S, Saxena S, Kufe D. Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine. Mol Pharmacol. 2002 Jun; 61(6):1489-95. PMID: 12021410.
    Citations: 6     Fields:    Translation:HumansCells
  62. Reimer CL, Agata N, Tammam JG, Bamberg M, Dickerson WM, Kamphaus GD, Rook SL, Milhollen M, Fram R, Kalluri R, Kufe D, Kharbanda S. Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis. Cancer Res. 2002 Feb 01; 62(3):789-95. PMID: 11830534.
    Citations: 10     Fields:    Translation:HumansAnimals
  63. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, Kahn CR, Sonenberg N, Hynes RO, Kalluri R. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science. 2002 Jan 04; 295(5552):140-3. PMID: 11778052.
    Citations: 107     Fields:    Translation:HumansAnimalsCells
  64. Kharbanda S, Pandey P, Yamauchi T, Kumar S, Kaneki M, Kumar V, Bharti A, Yuan ZM, Ghanem L, Rana A, Weichselbaum R, Johnson G, Kufe D. Activation of MEK kinase 1 by the c-Abl protein tyrosine kinase in response to DNA damage. Mol Cell Biol. 2000 Jul; 20(14):4979-89. PMID: 10866655; PMCID: PMC85948.
    Citations: 24     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Kharbanda's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (378)
Co-Authors (22)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.